x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DIA-0243161
| Product Information | |
|---|---|
| CAS No. | 1452387-69-7 |
| Synonyms | REGN1193; Anti-GCGR Reference Antibody (crotedumab) |
| SMILES | [Crotedumab] |
| Target | GCGR |
| Product Description | Crotedumab (REGN1193) is a fully human IgG4 monoclonal antibody that binds and inhibits glucagon receptor (GCGR), with a KD of 0.1 nM. Crotedumab can be used for the research of diabetes. |
| Format & Storage | |
|---|---|
| Format | Liquid |
| Color | Colorless to light yellow |
| Purity | 96.61% |
| Shipping | Shipping with dry ice. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
